Tegileridine Fumarate lnjection

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Abirritation in the ICU

Drug Information

Target Indication

Abirritation in the ICU

Clinical Trial

Last updated: 3/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Related Pipeline

Non-Small-Cell Lung Cancer

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

Primary Hypercholesterolemia

HER2-positive Breast Cancer

Nasopharyngeal Carcinoma

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts